发明名称 Medicament comprising NK4 gene or recombinant NK4 protein
摘要 The present invention provides a therapeutic agent which is effective for primary tumor of cancer and, more particularly, it provides an NK4 gene therapeutic agent and a recombinant NK4 protein preparation which is effective for the prevention and therapy of cancer. The present invention also provides a therapeutic agent which is effective for metastasis of cancer and, more particularly, it provides an NK4 gene therapeutic agent and a recombinant NK4 protein preparation which is effective for the prevention and therapy of metastasis of cancer. <??>The present invention further provides a therapeutic agent which is effective for diseases caused by neovascularization including cancer and, more particularly, it provides an NK4 gene therapeutic agent and a recombinant NK4 protein preparation which is effective for diseases caused by neovascularization. <H0> (Solving Means) </H0> <??>DNA containing a base sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 or DNA containing a DNA which hybridizes to the said DNA under a stringent condition.
申请公布号 EP1354891(A1) 申请公布日期 2003.10.22
申请号 EP20030003693 申请日期 2003.02.18
申请人 KRINGLE PHARMA INC.;NAKAMURA, TOSHIKAZU 发明人 NAKAMURA, TOSHIKAZU;MATSUMOTO, KUNIO
分类号 C12N15/09;A61K9/127;A61K31/711;A61K35/76;A61K38/00;A61K45/00;A61K48/00;A61P7/04;A61P17/06;A61P19/02;A61P27/02;A61P27/06;A61P29/00;A61P35/00;A61P35/02;A61P35/04;A61P43/00;C07K14/47;C07K14/475;C12N1/15;C12N1/19;C12N1/21;C12N5/08;C12N5/10;C12P21/02;(IPC1-7):C07K14/475;A61K38/18 主分类号 C12N15/09
代理机构 代理人
主权项
地址